View in EDS HTML Full Text PDF Full Text

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report.

Saved in:
Bibliographic Details
Title: Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report.
Authors: Chandra S; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States., Hansraj S; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States., Adhikari A; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States., Ponvilawan B; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States., Tolentino A; Saint Luke's Cancer Institute, Kansas City, MO, United States., Bansal D; Division of Hematology and Oncology, Endeavor Health, Evanston, IL, United States.
Source: Frontiers in oncology [Front Oncol] 2026 Apr 27; Vol. 16, pp. 1795399. Date of Electronic Publication: 2026 Apr 27 (Print Publication: 2026).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42125703
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chandra+S%22">Chandra S</searchLink>; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.<br /><searchLink fieldCode="AU" term="%22Hansraj+S%22">Hansraj S</searchLink>; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.<br /><searchLink fieldCode="AU" term="%22Adhikari+A%22">Adhikari A</searchLink>; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.<br /><searchLink fieldCode="AU" term="%22Ponvilawan+B%22">Ponvilawan B</searchLink>; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.<br /><searchLink fieldCode="AU" term="%22Tolentino+A%22">Tolentino A</searchLink>; Saint Luke's Cancer Institute, Kansas City, MO, United States.<br /><searchLink fieldCode="AU" term="%22Bansal+D%22">Bansal D</searchLink>; Division of Hematology and Oncology, Endeavor Health, Evanston, IL, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2026 Apr 27; Vol. 16, pp. 1795399. <i>Date of Electronic Publication: </i>2026 Apr 27 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42125703
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2026.1795399
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1795399
    Titles:
      – TitleFull: Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chandra S
      – PersonEntity:
          Name:
            NameFull: Hansraj S
      – PersonEntity:
          Name:
            NameFull: Adhikari A
      – PersonEntity:
          Name:
            NameFull: Ponvilawan B
      – PersonEntity:
          Name:
            NameFull: Tolentino A
      – PersonEntity:
          Name:
            NameFull: Bansal D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 04
              Text: 2026 Apr 27
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1